Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Thomas Flaig

Concepts (382)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
37
2024
196
9.410
 Why?
Prostatic Neoplasms
36
2022
925
5.950
 Why?
Kidney Neoplasms
23
2023
334
3.980
 Why?
Prostatic Neoplasms, Castration-Resistant
18
2021
41
3.900
 Why?
Antineoplastic Agents
28
2021
1897
3.570
 Why?
Antineoplastic Combined Chemotherapy Protocols
26
2022
1361
3.530
 Why?
Carcinoma, Renal Cell
18
2023
173
3.510
 Why?
Carcinoma, Transitional Cell
12
2024
54
3.340
 Why?
Androgen Antagonists
14
2020
70
2.660
 Why?
Pyrroles
7
2017
183
1.710
 Why?
Neoadjuvant Therapy
8
2024
305
1.700
 Why?
Indoles
7
2017
306
1.580
 Why?
Medical Oncology
5
2020
228
1.480
 Why?
Urologic Neoplasms
6
2023
25
1.440
 Why?
Neoplasm Metastasis
24
2021
530
1.400
 Why?
Abiraterone Acetate
9
2021
15
1.380
 Why?
Urothelium
3
2016
33
1.340
 Why?
Adenocarcinoma
7
2020
801
1.190
 Why?
Prednisone
14
2021
231
1.190
 Why?
Taxoids
7
2017
94
1.170
 Why?
Phenylurea Compounds
6
2016
84
1.150
 Why?
Antineoplastic Agents, Hormonal
8
2017
138
1.130
 Why?
Neoplasm Staging
13
2023
1180
1.130
 Why?
Mitoxantrone
5
2018
12
1.120
 Why?
Niacinamide
5
2016
64
1.070
 Why?
Prostate-Specific Antigen
11
2022
153
1.050
 Why?
Male
86
2023
55655
1.040
 Why?
Orchiectomy
4
2014
57
1.020
 Why?
Cisplatin
11
2024
263
0.980
 Why?
Humans
125
2024
114925
0.960
 Why?
Antibodies, Monoclonal, Humanized
8
2024
666
0.930
 Why?
Penile Neoplasms
1
2023
7
0.880
 Why?
Aged
52
2022
19120
0.850
 Why?
Phenylthiohydantoin
6
2021
40
0.820
 Why?
Carcinoma
2
2016
199
0.820
 Why?
Testicular Neoplasms
3
2023
97
0.800
 Why?
ErbB Receptors
6
2018
561
0.770
 Why?
Treatment Outcome
28
2023
9105
0.770
 Why?
Immunotherapy
5
2022
475
0.760
 Why?
Protein Kinase Inhibitors
6
2014
796
0.750
 Why?
Nitriles
10
2021
151
0.720
 Why?
Neoplasm Invasiveness
6
2024
445
0.720
 Why?
Aged, 80 and over
25
2021
6363
0.700
 Why?
Radiosurgery
4
2015
303
0.670
 Why?
Disease-Free Survival
12
2017
623
0.630
 Why?
Bone Neoplasms
3
2015
194
0.620
 Why?
Sulfonamides
2
2012
445
0.610
 Why?
Cystectomy
5
2024
32
0.600
 Why?
Viscera
2
2014
13
0.600
 Why?
Middle Aged
41
2021
26801
0.590
 Why?
Hematologic Diseases
2
2016
57
0.580
 Why?
Prostatectomy
5
2018
98
0.570
 Why?
Antineoplastic Agents, Immunological
2
2020
152
0.570
 Why?
Urinary Bladder
3
2023
164
0.560
 Why?
Benzamides
7
2021
169
0.560
 Why?
Erythrocytes, Abnormal
1
2016
13
0.560
 Why?
Practice Guidelines as Topic
3
2019
1400
0.560
 Why?
Liver Neoplasms
3
2017
509
0.550
 Why?
Prognosis
12
2023
3344
0.550
 Why?
Receptors, Androgen
2
2021
131
0.520
 Why?
Pancreatitis
1
2016
107
0.510
 Why?
Genomics
2
2018
641
0.510
 Why?
Silymarin
4
2013
194
0.480
 Why?
Leydig Cell Tumor
1
2014
8
0.460
 Why?
Epithelial-Mesenchymal Transition
2
2016
168
0.440
 Why?
Multicenter Studies as Topic
2
2021
250
0.420
 Why?
Chemotherapy, Adjuvant
7
2023
333
0.420
 Why?
Proto-Oncogene Proteins p21(ras)
1
2013
229
0.410
 Why?
Gene Expression Profiling
1
2018
1523
0.400
 Why?
Hypothyroidism
1
2012
65
0.400
 Why?
Administration, Intravesical
3
2022
14
0.400
 Why?
Carcinoma, Basal Cell
1
2013
68
0.400
 Why?
Sarcoma
1
2013
138
0.390
 Why?
Neoplasms, Germ Cell and Embryonal
2
2023
62
0.390
 Why?
Therapies, Investigational
1
2011
14
0.390
 Why?
Diethylstilbestrol
1
2011
9
0.390
 Why?
Angiomyolipoma
1
2011
17
0.390
 Why?
Antibodies, Monoclonal
5
2024
1270
0.380
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
103
0.380
 Why?
Disease Progression
10
2021
2392
0.370
 Why?
Pyrazoles
2
2023
364
0.370
 Why?
Leukemia, Myeloid, Acute
2
2008
536
0.370
 Why?
Neoplastic Cells, Circulating
1
2011
59
0.370
 Why?
Lung Neoplasms
5
2017
2222
0.360
 Why?
Androstenes
4
2015
11
0.360
 Why?
Retrospective Studies
12
2024
12543
0.350
 Why?
Molecular Targeted Therapy
1
2013
347
0.350
 Why?
United States
10
2023
12209
0.350
 Why?
Receptors, Fibroblast Growth Factor
1
2010
63
0.350
 Why?
Adult
25
2021
30604
0.340
 Why?
Neoplasm Proteins
1
2013
385
0.340
 Why?
Recombinant Fusion Proteins
1
2012
617
0.340
 Why?
Kaplan-Meier Estimate
8
2016
817
0.340
 Why?
Tumor Suppressor Protein p53
1
2013
447
0.340
 Why?
Neoplasms, Multiple Primary
1
2010
52
0.340
 Why?
SEER Program
4
2023
196
0.330
 Why?
Antineoplastic Agents, Phytogenic
2
2010
181
0.330
 Why?
Neoplasm Recurrence, Local
4
2022
863
0.330
 Why?
Lymphatic Diseases
1
2009
17
0.330
 Why?
Neuroblastoma
1
2010
132
0.320
 Why?
Vascular Endothelial Growth Factors
1
2009
61
0.320
 Why?
Cystitis
1
2009
20
0.320
 Why?
Vascular Endothelial Growth Factor A
2
2019
499
0.320
 Why?
Survival Rate
9
2021
1644
0.320
 Why?
Double-Blind Method
12
2021
1663
0.310
 Why?
Androstadienes
3
2013
97
0.310
 Why?
Female
26
2021
59571
0.310
 Why?
Pneumatosis Cystoides Intestinalis
1
2008
19
0.310
 Why?
Precision Medicine
1
2011
339
0.310
 Why?
Intestinal Perforation
1
2008
38
0.310
 Why?
Clinical Trials as Topic
5
2018
934
0.300
 Why?
Pyrimidines
1
2011
378
0.300
 Why?
Deoxycytidine
3
2024
138
0.300
 Why?
Muscles
3
2024
322
0.300
 Why?
Carcinoma, Squamous Cell
1
2013
584
0.300
 Why?
Pancreatic Neoplasms
1
2014
733
0.300
 Why?
Testosterone
3
2021
343
0.290
 Why?
Survival Analysis
6
2021
1220
0.280
 Why?
BCG Vaccine
2
2018
18
0.280
 Why?
Androgen Receptor Antagonists
3
2021
30
0.280
 Why?
Combined Modality Therapy
9
2020
1126
0.280
 Why?
Cell Line, Tumor
7
2018
2725
0.270
 Why?
Nanotubes
2
2018
41
0.270
 Why?
Quinazolines
4
2019
243
0.270
 Why?
Neoplasm Grading
6
2018
243
0.260
 Why?
Carboplatin
1
2006
135
0.260
 Why?
Gold
2
2018
106
0.260
 Why?
Skin Neoplasms
1
2013
762
0.260
 Why?
Tumor Microenvironment
3
2023
434
0.250
 Why?
Lymphatic Metastasis
2
2018
281
0.250
 Why?
Gonadotropin-Releasing Hormone
2
2020
188
0.250
 Why?
Drug Resistance, Neoplasm
3
2018
642
0.250
 Why?
Biomarkers, Tumor
4
2023
1054
0.250
 Why?
Randomized Controlled Trials as Topic
3
2021
1215
0.250
 Why?
Radiotherapy, Adjuvant
2
2018
182
0.240
 Why?
Societies, Medical
2
2018
677
0.240
 Why?
Drug Synergism
3
2011
316
0.230
 Why?
Dexamethasone
1
2006
317
0.230
 Why?
Androstenols
3
2015
4
0.220
 Why?
Dose-Response Relationship, Drug
5
2013
1856
0.220
 Why?
Tosyl Compounds
4
2018
14
0.220
 Why?
Drug Administration Schedule
4
2021
718
0.220
 Why?
Gene Expression Regulation, Neoplastic
2
2021
1148
0.220
 Why?
Vitamin D
1
2006
341
0.210
 Why?
Steroid 17-alpha-Hydroxylase
2
2014
4
0.210
 Why?
Cell-Free Nucleic Acids
1
2023
28
0.210
 Why?
Anilides
4
2018
67
0.210
 Why?
Quality of Life
4
2024
2359
0.200
 Why?
Sleep Initiation and Maintenance Disorders
1
2024
117
0.200
 Why?
Patient Reported Outcome Measures
2
2024
250
0.200
 Why?
Retroperitoneal Space
1
2021
15
0.200
 Why?
Thiohydantoins
1
2021
2
0.200
 Why?
Indazoles
2
2012
58
0.190
 Why?
Tissue Extracts
2
2012
20
0.190
 Why?
Databases, Factual
2
2016
1125
0.190
 Why?
Kallikreins
2
2019
30
0.190
 Why?
Retreatment
1
2021
67
0.190
 Why?
Bone Marrow Transplantation
1
2002
241
0.180
 Why?
Tomography, X-Ray Computed
4
2014
2326
0.180
 Why?
Time Factors
5
2020
6125
0.180
 Why?
Genetic Heterogeneity
1
2020
49
0.170
 Why?
Phosphatidylcholines
2
2013
133
0.170
 Why?
Angiogenesis Inhibitors
2
2021
215
0.160
 Why?
Yttrium
1
2018
5
0.160
 Why?
In Situ Hybridization, Fluorescence
2
2011
314
0.160
 Why?
Cell Adhesion Molecules
1
2020
168
0.160
 Why?
Fluorides
1
2018
43
0.160
 Why?
Euterpe
1
2018
6
0.160
 Why?
Central Nervous System
1
2020
238
0.160
 Why?
Organ Sparing Treatments
1
2018
31
0.160
 Why?
Piperidines
2
2010
162
0.160
 Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.150
 Why?
Lymph Node Excision
2
2021
142
0.150
 Why?
Odds Ratio
1
2021
954
0.150
 Why?
Congresses as Topic
2
2012
198
0.150
 Why?
Antioxidants
2
2013
530
0.150
 Why?
Apoptosis
1
2007
2371
0.150
 Why?
History, 21st Century
2
2015
161
0.150
 Why?
Tumor Escape
1
2018
36
0.150
 Why?
Cancer Vaccines
1
2019
138
0.150
 Why?
Genome
1
2020
272
0.150
 Why?
Neoplasm, Residual
2
2021
104
0.150
 Why?
Microscopy, Fluorescence
3
2018
398
0.150
 Why?
Proton Therapy
1
2017
10
0.140
 Why?
Blotting, Western
2
2010
1151
0.140
 Why?
Practice Patterns, Physicians'
2
2016
1177
0.140
 Why?
Goserelin
3
2018
8
0.140
 Why?
Biopsy
3
2018
1045
0.140
 Why?
Erythrocyte Indices
1
2016
28
0.140
 Why?
Plant Extracts
1
2018
155
0.140
 Why?
Aftercare
1
2018
187
0.140
 Why?
Oligopeptides
1
2018
235
0.140
 Why?
Dyslipidemias
1
2018
154
0.140
 Why?
Fatal Outcome
2
2008
285
0.140
 Why?
Watchful Waiting
1
2016
56
0.130
 Why?
Adverse Drug Reaction Reporting Systems
1
2016
68
0.130
 Why?
High-Throughput Nucleotide Sequencing
1
2018
441
0.130
 Why?
United States Food and Drug Administration
1
2016
172
0.130
 Why?
Prostate
2
2021
157
0.120
 Why?
Disease Management
1
2019
563
0.120
 Why?
Nanoparticles
1
2018
313
0.120
 Why?
Patient Selection
1
2018
642
0.120
 Why?
Soft Tissue Neoplasms
1
2015
90
0.120
 Why?
Radiation Tolerance
1
2015
92
0.120
 Why?
Insurance, Health
1
2016
244
0.120
 Why?
Cytochrome P-450 Enzyme Inhibitors
1
2014
4
0.120
 Why?
Ablation Techniques
1
2014
29
0.120
 Why?
Mitotic Index
1
2014
26
0.120
 Why?
Neoplasms, Hormone-Dependent
1
2014
38
0.110
 Why?
Magnetic Resonance Imaging
3
2021
3053
0.110
 Why?
Hyperthermia, Induced
1
2014
65
0.110
 Why?
Neoplasms, Complex and Mixed
1
2013
7
0.110
 Why?
Carcinoma, Medullary
1
2013
13
0.110
 Why?
Glucocorticoids
1
2018
534
0.110
 Why?
Receptor, ErbB-2
1
2016
301
0.110
 Why?
beta-Galactosidase
1
2013
62
0.110
 Why?
Breeding
1
2013
55
0.110
 Why?
Sirolimus
2
2014
181
0.110
 Why?
Geriatrics
1
2014
69
0.110
 Why?
Reproducibility of Results
2
2013
2769
0.110
 Why?
Brain Neoplasms
1
2021
987
0.110
 Why?
Interleukin-2
1
2014
419
0.110
 Why?
Staining and Labeling
1
2013
134
0.110
 Why?
Hyperplasia
1
2013
164
0.110
 Why?
Keratins
1
2013
176
0.110
 Why?
Urogenital Neoplasms
1
2012
5
0.110
 Why?
Cell Proliferation
2
2012
2199
0.110
 Why?
Tumor Stem Cell Assay
1
2012
33
0.110
 Why?
Organ Specificity
1
2013
270
0.110
 Why?
Nephrectomy
2
2013
149
0.110
 Why?
Population Surveillance
1
2015
392
0.110
 Why?
Adenoviridae
1
2013
185
0.100
 Why?
Integrases
1
2013
116
0.100
 Why?
Fluorescent Antibody Technique
1
2013
396
0.100
 Why?
Celecoxib
1
2012
38
0.100
 Why?
Thyroid Hormones
1
2012
54
0.100
 Why?
Thyroid Gland
1
2012
84
0.100
 Why?
Quinolines
1
2013
129
0.100
 Why?
RNA, Untranslated
1
2013
113
0.100
 Why?
Bone Diseases
1
2012
57
0.100
 Why?
Cross-Over Studies
3
2021
441
0.100
 Why?
Reoperation
1
2014
515
0.100
 Why?
Carcinoma, Hepatocellular
1
2013
213
0.100
 Why?
Imidazoles
1
2012
211
0.100
 Why?
Denosumab
1
2010
7
0.090
 Why?
PubMed
1
2010
10
0.090
 Why?
RANK Ligand
1
2010
26
0.090
 Why?
Animals
5
2016
31837
0.090
 Why?
Benzenesulfonates
1
2010
20
0.090
 Why?
Neoplasms
2
2022
2106
0.090
 Why?
Erlotinib Hydrochloride
1
2010
65
0.090
 Why?
Vimentin
1
2010
58
0.090
 Why?
Insulin-Like Growth Factor Binding Protein 3
1
2010
38
0.090
 Why?
Xenograft Model Antitumor Assays
1
2012
706
0.090
 Why?
Cell Separation
1
2011
292
0.090
 Why?
Hypertension
1
2018
1059
0.090
 Why?
Mesoderm
1
2010
138
0.080
 Why?
Cardiovascular Diseases
2
2018
1729
0.080
 Why?
Tumor Cells, Cultured
1
2011
855
0.080
 Why?
Cadherins
1
2010
176
0.080
 Why?
Carcinoma, Papillary
1
2009
73
0.080
 Why?
Age Factors
1
2016
2891
0.080
 Why?
Nephrolithiasis
1
2009
10
0.080
 Why?
Metaplasia
1
2009
54
0.080
 Why?
Gynecomastia
1
2008
4
0.080
 Why?
Chromatography, Liquid
1
2010
348
0.080
 Why?
Risk Factors
5
2018
8637
0.080
 Why?
Risk
1
2011
815
0.080
 Why?
Genotype
1
2013
1775
0.080
 Why?
Mice, Transgenic
1
2013
1953
0.080
 Why?
Drug Therapy, Combination
1
2011
954
0.080
 Why?
Proportional Hazards Models
3
2016
1080
0.080
 Why?
Tandem Mass Spectrometry
1
2010
413
0.080
 Why?
Southwestern United States
1
2008
91
0.080
 Why?
Insulin-Like Growth Factor I
1
2010
286
0.080
 Why?
Liver Failure, Acute
1
2008
58
0.080
 Why?
Hormone Replacement Therapy
1
2008
77
0.070
 Why?
Mediastinal Diseases
1
2007
10
0.070
 Why?
Carcinoid Tumor
1
2007
25
0.070
 Why?
Pyridines
1
2010
425
0.070
 Why?
Mice
2
2013
14935
0.070
 Why?
Glucuronides
1
2006
12
0.070
 Why?
Neoplasms, Second Primary
1
2008
94
0.070
 Why?
Spectrophotometry, Ultraviolet
1
2006
74
0.070
 Why?
Medical History Taking
1
2007
114
0.070
 Why?
Excipients
1
2006
49
0.070
 Why?
Liver Function Tests
1
2006
103
0.070
 Why?
Chemistry, Pharmaceutical
1
2006
98
0.070
 Why?
Syndrome
1
2007
336
0.070
 Why?
Antibiotics, Antineoplastic
1
2006
109
0.070
 Why?
Spectrometry, Mass, Electrospray Ionization
1
2006
162
0.070
 Why?
Pedigree
1
2007
467
0.070
 Why?
Everolimus
2
2017
61
0.060
 Why?
Sarcoidosis
1
2007
135
0.060
 Why?
Radiography
1
2008
819
0.060
 Why?
Signal Transduction
2
2016
4524
0.060
 Why?
Doxorubicin
1
2006
286
0.060
 Why?
Forecasting
1
2007
333
0.060
 Why?
Metabolic Syndrome
1
2008
323
0.060
 Why?
Biomarkers
2
2023
3418
0.060
 Why?
Epithelial Cells
1
2010
958
0.060
 Why?
DNA Damage
1
2007
357
0.060
 Why?
Gastrointestinal Diseases
1
2006
183
0.060
 Why?
Melanoma
1
2011
631
0.060
 Why?
Diagnosis, Differential
1
2009
1355
0.060
 Why?
Referral and Consultation
1
2009
634
0.060
 Why?
Radiotherapy
2
2015
176
0.060
 Why?
Carcinoma, Non-Small-Cell Lung
1
2012
975
0.060
 Why?
Young Adult
4
2021
10476
0.050
 Why?
Disease Models, Animal
1
2012
3549
0.050
 Why?
Follow-Up Studies
2
2015
4427
0.050
 Why?
Immunohistochemistry
2
2020
1635
0.050
 Why?
Maximum Tolerated Dose
2
2013
184
0.050
 Why?
Immune System Diseases
1
2002
34
0.050
 Why?
Steroid Synthesis Inhibitors
1
2021
1
0.050
 Why?
Policy
1
2022
137
0.050
 Why?
Proteomics
1
2007
844
0.050
 Why?
Clinical Trials, Phase III as Topic
1
2021
82
0.050
 Why?
Mass Screening
1
2008
1011
0.050
 Why?
Prednisolone
1
2021
77
0.050
 Why?
Metabolic Diseases
1
2002
96
0.050
 Why?
Tumor Burden
1
2021
262
0.050
 Why?
Bevacizumab
1
2021
115
0.050
 Why?
Phosphatidylinositol 3-Kinases
1
2022
330
0.050
 Why?
Asymptomatic Diseases
1
2021
75
0.040
 Why?
Proto-Oncogene Proteins c-akt
1
2022
400
0.040
 Why?
TOR Serine-Threonine Kinases
1
2022
359
0.040
 Why?
Neovascularization, Pathologic
1
2021
283
0.040
 Why?
Ytterbium
1
2018
2
0.040
 Why?
Erbium
1
2018
5
0.040
 Why?
HLA-A2 Antigen
1
2019
36
0.040
 Why?
Hospitals
1
2023
581
0.040
 Why?
Estrogen Receptor alpha
1
2020
121
0.040
 Why?
Risk Assessment
1
2008
2975
0.040
 Why?
DNA Methylation
1
2023
496
0.040
 Why?
Fruit and Vegetable Juices
1
2018
12
0.040
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
243
0.040
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2019
140
0.040
 Why?
Luminescent Measurements
1
2018
74
0.040
 Why?
Lasers
1
2018
121
0.040
 Why?
Pain
1
2024
710
0.040
 Why?
Laparoscopy
1
2021
389
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
40
0.040
 Why?
Antibodies
1
2018
372
0.030
 Why?
Risk Reduction Behavior
1
2018
200
0.030
 Why?
DNA
1
2023
1351
0.030
 Why?
Abdominal Neoplasms
1
2015
26
0.030
 Why?
Molecular Diagnostic Techniques
1
2016
92
0.030
 Why?
Thoracic Neoplasms
1
2015
33
0.030
 Why?
Placebos
1
2015
198
0.030
 Why?
Radiotherapy Planning, Computer-Assisted
1
2015
119
0.030
 Why?
Administration, Oral
1
2017
731
0.030
 Why?
Nanoconjugates
1
2014
1
0.030
 Why?
Antihypertensive Agents
1
2018
429
0.030
 Why?
Spectrophotometry, Atomic
1
2014
13
0.030
 Why?
Platelet Aggregation Inhibitors
1
2018
400
0.030
 Why?
Lipids
1
2018
582
0.030
 Why?
Radiotherapy, Intensity-Modulated
1
2015
125
0.030
 Why?
Smoking Cessation
1
2018
374
0.030
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2018
372
0.030
 Why?
Benchmarking
1
2015
161
0.030
 Why?
Accidental Falls
1
2015
150
0.030
 Why?
Cell Death
1
2014
325
0.030
 Why?
Blood Pressure
1
2018
1537
0.020
 Why?
Prospective Studies
1
2023
6218
0.020
 Why?
Hydroxamic Acids
1
2012
80
0.020
 Why?
Health Policy
1
2014
334
0.020
 Why?
Dose-Response Relationship, Radiation
1
2011
128
0.020
 Why?
Histone Deacetylase Inhibitors
1
2012
198
0.020
 Why?
Androgens
1
2011
167
0.020
 Why?
Polyethylene Glycols
1
2014
560
0.020
 Why?
Seizures
1
2012
340
0.020
 Why?
Fatigue
1
2011
296
0.020
 Why?
Sex Factors
1
2014
1721
0.020
 Why?
Multivariate Analysis
1
2012
1440
0.020
 Why?
Positron-Emission Tomography
1
2009
265
0.020
 Why?
Radionuclide Imaging
1
2007
115
0.020
 Why?
Cell Membrane Permeability
1
2006
83
0.020
 Why?
Head and Neck Neoplasms
1
2008
436
0.010
 Why?
Cell Survival
1
2006
1022
0.010
 Why?
Ultrasonography
1
2006
633
0.010
 Why?
Incidence
1
2008
2316
0.010
 Why?
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (382) concept(s)
_
Co-Authors Expand Description
See all (47) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)